Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Chronic myeloid leukemia | R-HSA-9680350 | map05220 | vorinostat | 5311 | drug-path |
| Complement and coagulation cascades | R-HSA-114591 | map04610 | vorinostat | 5311 | drug-path |
| Glioma | Q9NZM4 | map05214 | alvespimycin | 43815 | drug-path |
| Antigen processing and presentation | R-HSA-1236975 | map04612 | alvespimycin | 43815 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | alvespimycin | 43815 | drug-path |
| Focal adhesion | R-HSA-354113 | map04510 | alvespimycin | 43815 | drug-path |
| Pancreatic cancer | R-HSA-9700206 | map05212 | alvespimycin | 43815 | drug-path |
| Prostate cancer | R-HSA-2990872 | map05215 | alvespimycin | 43815 | drug-path |
| Vascular smooth muscle contraction | R-HSA-445355 | map04270 | alvespimycin | 43815 | drug-path |
| Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | alvespimycin | 43815 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | alvespimycin | 43815 | drug-path |
| PPAR signaling pathway | R-HSA-168638 | map03320 | alvespimycin | 43815 | drug-path |
| Alzheimer's disease | R-HSA-1643685 | 0 | alvespimycin | 43815 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | alvespimycin | 43815 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | alvespimycin | 43815 | drug-path |
| Jak-STAT signaling pathway | R-HSA-168638 | map04630 | alvespimycin | 43815 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | alvespimycin | 43815 | drug-path |
| Cardiac muscle contraction | R-HSA-397014 | map04260 | alvespimycin | 43815 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | alvespimycin | 43815 | drug-path |
| Ribosome | R-HSA-5368277 | map03010 | alvespimycin | 43815 | drug-path |